Location History:
- Berardenga, IT (2015)
- Siena, IT (2000 - 2019)
- Castelnuovo Berardenga, IT (2019 - 2020)
Company Filing History:
7 out of 531 
3 out of 3,923 
1 out of 47 Years Active: 2000-2020
Title: Maurizio Comanducci: Innovator in Meningococcal Vaccine Development
Introduction
Maurizio Comanducci is a prominent inventor based in Siena, Italy. He has made significant contributions to the field of vaccine development, particularly in the area of meningococcal vaccines. With a total of 14 patents to his name, Comanducci's work has had a substantial impact on public health.
Latest Patents
One of Comanducci's latest patents focuses on adjuvanted combinations of meningococcal factor H binding proteins. The M01573 sequence of meningococcal fHbp offers poor coverage in a vaccine. This invention addresses the issue of poor coverage in two innovative ways. In the first aspect, a fHbp-based vaccine includes two family I fHbp sequences, one which is more closely related to MC58 than to M01573, and vice versa. In the second aspect, a multi-family fHbp-based vaccine utilizes a family I fHbp sequence that is more closely related to MC58 than to M01573, in combination with a family III fHbp sequence. The compositions are adjuvanted with an aluminium phosphate adjuvant, enhancing their effectiveness.
Career Highlights
Throughout his career, Comanducci has worked with leading pharmaceutical companies, including GlaxoSmithKline Biologicals SA and Novartis AG. His expertise in vaccine development has positioned him as a key figure in the industry, contributing to advancements that improve vaccine efficacy and safety.
Collaborations
Comanducci has collaborated with notable colleagues such as Mariagrazia Pizza and Cesira Galeotti. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of vaccine research.
Conclusion
Maurizio Comanducci's contributions to meningococcal vaccine development exemplify the importance of innovation in public health. His patents and collaborations continue to pave the way for advancements in vaccine technology, ultimately benefiting society as a whole.